

=> d his

(FILE 'HOME' ENTERED AT 06:13:43 ON 10 OCT 2002)
SET COST OFF

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

FILE 'REGISTRY' ENTERED AT 06:13:50 ON 10 OCT 2002
L1 3 S 112111-47-4 OR 112111-43-0 OR 68693-11-8

FILE 'HCAPLUS' ENTERED AT 06:14:48 ON 10 OCT 2002
L2 144 S L1
L3 3 S L1 (L) PRP/RL
E SOLUBILITY/CT
E E3+ALL
L4 19368 S E3,E4,E2+NT
L5 13918 S E24+NT
L6 37949 S E26+NT OR E27+NT OR E29+NT OR E32+NT
L7 1 S L2 AND L4-L6
L8 157 S MODAFINIL OR PROVIGIL OR MODIODAL OR CEP1538 OR CEP 1538 OR C
L9 0 S 2 BENZHYDRYLSULFINYL ACETAMIDE
L10 2 S BENZHYDRYLSULFINYL ACETAMIDE
L11 0 S BENZHYDRYL SULFINYL ACETAMIDE
L12 0 S BENZHYDRYL SULFINYLACETAMIDE
L13 6 S BENZHYDRYLSULFINYLACETAMIDE
L14 2 S DIPHENYLMETHYL SULFINYL ACETAMIDE
L15 0 S DIPHENYLMETHYL SULPHINYL ACETAMIDE
L16 0 S DIPHENYLMETHYLSULFINYL ACETAMIDE
L17 0 S DIPHENYLMETHYLSULFINYLACETAMIDE
L18 0 S DIPHENYL METHYLSULFINYL ACETAMIDE
L19 0 S DIPHENYL METHYL SULFINYL ACETAMIDE
L20 0 S DIPHENYL METHYL SULFINYLACETAMIDE
L21 0 S DIPHENYL METHYLSULFINYLACETAMIDE
L22 1 S L4-L6 AND L8,L10,L13,L14
L23 3 S L3,L7,L22
E BIOLOGICAL TRANSPORT/CT
E E3+ALL
L24 261937 S E4+NT
L25 7 S L2,L8 AND L24
L26 9 S L23,L25
L27 9 S L26 AND L2-L26

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 06:20:58 ON 10 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Oct 2002 VOL 137 ISS 15
FILE LAST UPDATED: 9 Oct 2002 (20021009/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d 127 bib abs hitstr tot

L27 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:354556 HCAPLUS

DN 137:98838

TI Molecular Properties That Influence the Oral Bioavailability of Drug Candidates

AU Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.

CS Departments of Medicinal Chemistry, Cheminformatics, Computational Analytical and Structural Sciences, and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, PA, 19406-0939, USA

SO Journal of Medicinal Chemistry (2002), 45(12), 2615-2623
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property. Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt. That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability. The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set. Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area .ltoreq.140 .ANG.2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat. Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd. Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate. A threshold permeation rate is a prerequisite of oral bioavailability. The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.


IT **68693-11-8, Modafinil**

RL: PKT (Pharmacokinetics); PRP (**Properties**); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mol. properties effect on oral bioavailability of drug candidates)

RN 68693-11-8 HCAPLUS

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:107306 HCAPLUS

DN 136:167176
 TI Oxidative process for the preparation of crystalline and pure
modafinil and process for producing new **modafinil**
 crystal morphologs
 IN Singer, Claude; Gershon, Neomi; Ceausu, Arina; Lieberman, Anita; Aronhime,
 Judith
 PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA,
 Inc.
 SO PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010125	A1	20020207	WO 2001-US23689	20010727
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002043207	A1	20020418	US 2001-916885	20010727
PRAI	US 2000-221110P	P	20000727		
	US 2000-226491P	P	20000818		
	US 2000-229160P	P	20000830		
	US 2000-230088P	P	20000905		
	US 2001-259332P	P	20010102		
AB	High-purity modafinil is prepd. by: (a) oxidizing 2-[(diphenylmethyl)thio]acetamide with aq. H2O2 in a mixt. of a mineral acid with an alc. or phase transfer catalyst; (b) pptg. a solid-contg. modafinil from the mixt.; and (c) sepg. the mixt. from the pptd. solid modafinil free of sulfone byproducts of over-oxidn. and other byproducts. New cryst. Forms II-VI of modafinil and processes for prepg. them using heating and crystn are presented; X-ray powder diffractograms of the new crystal modafinil forms are presented.				
IT	68693-11-8P, Modafinil RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (oxidative process for the prepn. of cryst. and pure modafinil and process for producing new modafinil crystal morphologs)				
RN	68693-11-8 HCAPLUS				
CN	Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)				



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 2002:104621 HCAPLUS
 DN 136:145265
 TI A pharmaceutical composition for the treatment of attention deficit

hyperactivity disorder (ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent

IN Watsky, Eric Jacob; Coe, Jotham Wadsworth; Harrigan, Edmund Patrick; O'Neill, Brian Thomas; Sands, Steven Bradley

PA Pfizer Products Inc., USA


SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1177798	A2	20020206	EP 2001-306455	20010727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 2002016334	A1	20020207	US 2001-865793	20010525
	BR 2001003169	A	20020528	BR 2001-3169	20010731
PRAI	US 2000-221718P	P	20000731		
AB	Pharmaceutical compns. are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compns. are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.				
IT	68693-11-8, Modafinil RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nicotine receptor partial agonist and anti-attention deficit hyperactivity disorder agent for pharmaceutical compn. for treatment of attention deficit hyperactivity disorder)				
RN	68693-11-8 HCAPLUS				
CN	Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)				



L27 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:560443 HCAPLUS

DN 135:338915

TI Optimization of a mathematical topological pattern for the prediction of antihistaminic activity

AU Duarte, M. J.; Garcia-Domenech, R.; Anton-Fos, G. M.; Galvez, J.

CS Departamento Ciencias Quimicas, Universidad Cardenal Herrera-CEU, Spain

SO Journal of Computer-Aided Molecular Design (2001), 15(6), 561-572
CODEN: JCADEQ; ISSN: 0920-654X

PB Kluwer Academic Publishers

DT Journal

LA English


AB Mol. topol. was used to develop a math. model capable of classifying compds. according to antihistaminic activity. The equations used for this purpose were derived using multi-linear regression and linear discriminant anal. The topol. pattern of activity obtained allows the reliable prediction of antihistaminic activity in drugs frequently used for other therapeutic purposes. Based on the results, the proposed pattern is seemingly only valid for drugs that interact with histamine through competitive inhibition with H1 receptors.

IT **68693-11-8, Modafinil**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(optimization of a math. topol. pattern for the prediction of
antihistaminic activity)

RN 68693-11-8 HCAPLUS

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:182256 HCAPLUS

DN 135:28931

TI **Modafinil** does not affect serotonin efflux from rat frontal
cortex synaptosomes: comparison with known serotonergic drugs

AU Ferraro, L.; Tanganelli, S.; Fuxe, K.; Bebe, B. W.; Tomasini, M. C.;
Rambert, F. A.; Antonelli, T.

CS Section of Pharmacology, Department of Clinical and Experimental Medicine,
University of Ferrara, Ferrara, 44100, Italy

SO Brain Research (2001), 894(2), 307-310

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB **Modafinil** did not affect spontaneous and K+-evoked [3H]5-HT
efflux from cortical synaptosomes while it increased K+-evoked tritium
efflux from cortical slices, an action that became stronger in the
presence of paroxetine. In contrast, DL-fenfluramine and fluoxetine were
able to enhance spontaneous and/or K+-evoked tritium efflux from
synaptosomes and slices. These results suggest that **modafinil**
does not affect 5-HT transmission from cortical synaptosomes and that its
5-HT releasing action is different from that of DL-fenfluramine and
fluoxetine.


IT 68693-11-8, **Modafinil**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(**modafinil** does not affect serotonin efflux from rat frontal
cortex synaptosomes)

RN 68693-11-8 HCAPLUS

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:481971 HCAPLUS

DN 134:80725

TI Antiparkinsonian and neuroprotective effects of **modafinil** in the
MPTP-treated common marmoset

AU Jenner, P.; Zeng, B.-Y.; Smith, L. A.; Pearce, R. K. B.; Tel, B.;
Chancharme, L.; Moachon, G.

CS King's and St Thomas' School of Biomedical Sciences, Guy's, Division of

Pharmacology and Therapeutics, Neurodegenerative Disease Research Centre,
King's College, London, SE1 1UL, UK

SO Experimental Brain Research (2000), 133(2), 178-188
CODEN: EXBRAP; ISSN: 0014-4819

PB Springer-Verlag

DT Journal

LA English

AB The psychostimulant drug, **modafinil**, protects rodents against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity, striatal ischemia and partial transection of the nigro-striatal pathway. We now report on the ability of **modafinil** to reverse motor disability in MPTP-treated common marmosets and to prevent MPTP-induced nigral cell death in this species. In the initial expts., adult common marmosets were treated with MPTP to produce stable motor deficits. The subsequent administration of **modafinil** (10, 30 or 100 mg/kg/day, p.o.) produced a dose-dependent reversal of motor disability. In a subsequent expt., normal common marmosets were concurrently treated with 10, 30 or 100 mg/kg of **modafinil** once daily by gavage during acute MPTP administration (daily for 5 days), continuing for 2 wk after the last dose of MPTP. **Modafinil** dose-dependently prevented the decline in motor activity normally produced by MPTP treatment. MPTP treatment caused a 76% loss of nigral tyrosine-hydroxylase-immunoreactive cells in placebo-treated animals, and this was dose-dependently prevented by **modafinil**. At the highest dose (100 mg/kg/day) of **modafinil**, there was no significant loss of tyrosine-hydroxylase-immunoreactive cells in the substantia nigra compared with normal animals. MPTP treatment also reduced striatal dopamine uptake sites by 95%, as measured by specific [3H]-mazindol binding, compared with normal controls. **Modafinil** treatment dose-dependently reduced the loss of specific [3H]-mazindol binding. Behavioral and morphol. evidence in the present study indicate a potential antiparkinsonian and neuroprotective role for **modafinil**, which may form a new pharmacol. approach to the treatment of Parkinson's disease.


IT 68693-11-8, **Modafinil**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiparkinsonian and neuroprotective effects of **modafinil** in MPTP-treated common marmoset)

RN 68693-11-8 HCAPLUS

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:200477 HCAPLUS

DN 131:39566

TI The vigilance-promoting drug **modafinil** increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade


AU Ferraro, Luca; Antonelli, Tiziana; Tanganelli, Sergio; O'Connor, William T.; De la Mora, Miguel Perez; Mendez-Franco, Jesus; Rambert, Francis A.; Fuxe, Kjell

CS Department of Clinical and Experimental Medicine, Pharmacology Section, University of Ferrara, Ferrara, Italy

SO Neuropsychopharmacology (1999), 20(4), 346-356
 CODEN: NEROEW; ISSN: 0893-133X
 PB Elsevier Science Inc.
 DT Journal
 LA English
 AB The effects of **modafinil** on glutamatergic and GABAergic transmission in the rat medial preoptic area (MPA) and posterior hypothalamus (PH) were analyzed. **Modafinil** (30-300 mg/kg) increased glutamate and decreased GABA concns. in the MPA and PH. Local perfusion with the GABAA agonist muscimol (10 .mu.M) reduced, while the GABAA antagonist bicuculline (1 .mu.M and 10 .mu.M) increased, glutamate. The **modafinil** (100 mg/kg)-induced increase of glutamate was antagonized by local perfusion with bicuculline (1 .mu.M). When glutamate concns. were increased by local perfusion with the glutamate uptake inhibitor L-trans-PDC (0.5 mM), **modafinil** produced an addnl. enhancement of glutamate concns. **Modafinil** (1-33 .mu.M) failed to affect [3H]glutamate uptake in hypothalamic synaptosomes and slices. These findings show that **modafinil** increases glutamate and decreases GABA in the MPA and PH. The evidence that bicuculline counteracts the **modafinil**-induced increase of glutamate strengthens the evidence for an inhibitory GABA/glutamate interaction in the above regions, which control the sleep-wakefulness cycle.

IT 68693-11-8, **Modafinil**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (modafinil effects on extracellular glutamate and GABA in the medial preoptic area and the posterior hypothalamus)

RN 68693-11-8 HCAPLUS
 CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2002 ACS
 AN 1996:439446 HCAPLUS
 DN 125:104992
 TI The vigilance promoting drug **modafinil** increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism

AU Ferraro, Luca; Tanganelli, Sergio; O'Connor, William Thomas; Antonelli, Tiziana; Rambert, Francis; Fuxe, Kjell
 CS Institute of Pharmacology, University of Ferrara, Ferrara, Italy
 SO European Journal of Pharmacology (1996), 306(1-3), 33-39
 CODEN: EJPHAZ; ISSN: 0014-2999
 PB Elsevier
 DT Journal
 LA English
 AB The present in vivo microdialysis study demonstrated that the s.c. injection of **modafinil** (diphenyl-methyl-sulfinyl-2-acetamide) in doses of 30-300 mg/kg dose dependently increased dopamine release from the intermediate level of the nucleus accumbens along the rostro-caudal axis of the halothane anesthetized rat. The effect of **modafinil** in a dose of 100 mg/kg was counteracted by the local perfusion in the nucleus accumbens with the GABAB receptor antagonist phaclofen (.beta.-p-chlorophenyl-.gamma.-aminopropyl-phosphonic acid) (50 .mu.M), the GABAA agonist muscimol (3-hydroxy-5-aminomethyl-isoxazolol) (10 .mu.M) and the neuronal GABA reuptake inhibit SKF89976A (4,4-diphenyl-3-butenyl-

nipecotic acid) (0.1 .mu.M), where it was increased by the GABAB receptor agonist (-)-baclofen [.beta.-(p-chlorophenyl-.gamma.-aminobutyric acid)] (1- .mu.M). In addn., the **modafinil**-induced increase of dopamine release was assocd. with a significant redn. of accumbens GABA release. These results suggest that the dopamine releasing action of **modafinil** in the rat nucleus accumbens is secondary to its ability to reduce local GABAergic transmission, which leads to a redn. of GABAA receptor signaling on the dopamine terminals.


IT 68693-11-8, **Modafinil**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(the vigilance promoting drug **modafinil** increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism)

RN 68693-11-8 HCAPLUS

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2002 ACS

AN 1992:248290 HCAPLUS

DN 116:248290

TI Inhibitory effects of the psychoactive drug **modafinil** on .gamma.-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig. Possible involvement of 5-hydroxytryptamine mechanisms

AU Tanganelli, S.; Fuxe, K.; Ferraro, L.; Janson, A. M.; Bianchi, C.

CS Dep. Pharmacol., Univ. Ferrara, Ferrara, Italy

SO Naunyn-Schmiedeberg's Archives of Pharmacology (1992), 345(4), 461-5
CODEN: NSAPCC; ISSN: 0028-1298

DT Journal

LA English


AB The effects of **modafinil** on acetylcholine and GABA outflow from the cerebral cortex of awake freely moving guinea pigs provided with an epidural cup were studied. In the dose range of 3-30 mg/kg s.c., **modafinil** produced a dose dependent significant inhibition of GABA outflow without influencing cortical acetylcholine release. Methysergide (2 mg/kg, i.p.) and ketanserin (0.5 mg/kg, i.p.) but not prazosin (0.14 mg/kg, i.p.) counteracted the inhibitory action of **modafinil** on cortical GABA outflow. **Modafinil** both acutely and chronically in the same dose range increased striatal 5-HIAA levels and 5-HT utilization in the rat (acute) and mouse (chronic). The action on cortical GABA release may be dependent on activity at 5-HT2 receptors, since the action of **modafinil** in this respect is blocked by the non-selective 5-HT antagonist methysergide and the 5-HT2 antagonist ketanserin. The involvement of 5-HT mechanisms in the inhibitory action of **modafinil** on cortical GABA release is also suggested by the findings that 5-HT metab. may become increased by **modafinil** at least in the striatum. The redn. of cortical GABA outflow via 5-HT2 receptors by **modafinil** is probably related to some of its actions on the central nervous system including behavioral effects.

IT 68693-11-8, **Modafinil**

RL: BIOL (Biological study)
(acetylcholine and GABA release response to, in brain cortex, serotonergic 52 receptor mediation of)

RN 68693-11-8 HCAPLUS

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



=> fil mrck

FILE 'MRCK' ENTERED AT 06:22:43 ON 10 OCT 2002

COPYRIGHT (C) 1996, 2002 Merck & Co., Inc., Whitehouse Station, N. J.

FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: APRIL 2001

Merck & Co., Inc. cannot be responsible for errors in publication or for any consequences arising from use of the information contained in THE MERCK INDEX ONLINE. Reference to original sources is encouraged.

THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, N. J., USA.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all

L30 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 1996, 2002 MERCK & CO., INC., Whitehouse Station, N. J.

MERCK Number (MNO): 6311

CAS Registry No. (RN): 68693-11-8

MERCK Index Name (MIN): Modafinil

CA Index Name (CN): 2-[(Diphenylmethyl)sulfinyl]acetamide

Synonym(s) (CN): 2-(benzhydrylsulfinyl)acetamide

Drug Code(s) (CN): CRL-40476

Trade Name(s) (CN): Provigil (Cephalon)

Molecular Form. (MF): C15 H15 N O2 S

Wgt Composition (COMP): C 65.91%, H 5.53%, N 5.12%, O 11.71%, S 11.73%.

Molecular Weight (MW): 273.36

References (RE): .alpha.1-Adrenergic agonist. Prepn: L. Lafon, Ger.

pat. 2809625; eidem, U.S. pat. 4177290 (1978, 1979 both to Lab. Lafon).


Effects on vigilance: F. Goldenberg, J. S. Weil, Sleep (Stuttgart) 8, 343

(1988); on normal sleep: B. Saletu et al., Int. J. Clin. Pharmacol. Res.

9, 183 (1989). Clinical evaluation in hypersomnia and narcolepsy: H.

Bastuji, M. Jouvet, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 12, 695

(1988).



Melting Point (MP):

Value

MP

deg C

=====
164 - 166

Other Properties (OCPP):

Crystals from methanol, mp 164-166.degree..

Therapeutic Codes (THER):
CNS Stimulant.
Referenced Patent (RPN):
DE2809625; US4177290

=> d his

(FILE 'HOME' ENTERED AT 13:42:03 ON 09 OCT 2002)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 13:42:25 ON 09 OCT 2002
E MODAFINIL/CN

L1 1 S E3
L2 1 S E4
L3 431 S C15H15NO2S/MF AND 46.150.18/RID AND 2/NR
L4 37 S L3 AND ACETAMIDE
L5 4 S L4 AND DIPHENYLMETHYL
L6 3 S L5 NOT HYDROXY
L7 3 S L1,L6 AND MODAFINIL
L8 333 S C15H14O3S/MF AND 46.150.18/RID AND 2/NR
L9 3 S L8 AND ACETIC ACID AND DIPHENYLMETHYL
L10 3 S L2,L9
SEL RN L7
L11 5 S E1-E3/CRN
SEL RN L10
L12 2 S E4-E6/CRN

FILE 'HCAOLD' ENTERED AT 14:16:11 ON 09 OCT 2002

L13 0 S L7
L14 0 S L11

FILE 'HCAPLUS' ENTERED AT 14:16:11 ON 09 OCT 2002

L15 1 S L11
L16 143 S L7
L17 157 S MODAFINIL OR PROVIGIL OR MODIODAL OR CRL40476 OR CRL() (40476
L18 160 S L16,L17
L19 3 S L18 AND ?CYCLODEXTRIN?

FILE 'REGISTRY' ENTERED AT 14:21:31 ON 09 OCT 2002

L20 6 S 12619-70-4 OR 10016-20-3 OR 7585-39-9 OR 17465-86-0 OR 85220-
L21 22279 S (13750 OR 14099 OR 14246 OR 30188 OR 57602)/RID
L22 23429 S ?CYCLODEXTRIN?/CNS
L23 23725 S L21,L22 NOT L20

FILE 'HCAPLUS' ENTERED AT 14:24:01 ON 09 OCT 2002

L24 14041 S L20
L25 10005 S L23
L26 2 S L18 AND L24,L25
L27 3 S L15,L19,L26
L28 2 S L27 NOT CHROMATOGRAPHY/TI
E JACOBS M/AU
L29 170 S E3,E15-E18
E JACOBS MARTIN/AU
L30 19 S E3,E8,E9
E MARTIN J/AU
L31 4190 S E3-E82,E94-E96
E PIYUSH P/AU
L32 1 S E2
E PATEL P/AU
L33 812 S E3-E24
E PATEL PIYUSH/AU
L34 33 S E3-E8
L35 3 S L18 AND L29-L34
E CEPHALON/PA,CS
L36 270 S E3-E23
L37 21 S L18 AND L36
L38 2 S L35,L37 AND (L24,L25 OR ?CYCLODEXTRIN?)
L39 5 S L26-L28,L35,L38

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

L40 1 S L39 AND L11
L41 5 S L39,L40
E DRUG BIOAVAILABILITY/CT
E E3+ALL
L42 13090 S E3
E E6+ALL
L43 3389 S E5,E4+NT
E E9+ALL
L44 6372 S E2+NT
E PHARMACOKINETICS/CT
E E3+ALL
L45 12487 S E2+NT
E E11+ALL
L46 57131 S E3+NT
L47 12 S L18 AND L42-L46
SEL DN AN 8
L48 1 S L47 AND E1-E3
L49 97 S L7 (L) (ADV OR BCP OR BPR OR BSU OR DMA OR MFM OR PAC OR PKT)
L50 97 S L49 AND L18
L51 2 S L41,L48 AND L50
L52 6 S L41,L48,L51
L53 85 S L50 NOT L52,L47
SEL DN AN 31 38 50 52 55 58 62 63 71 72
L54 10 S L53 AND E4-E33
L55 16 S L52,L54
L56 59 S L18 NOT L47-L55
SEL DN AN 22 25
L57 2 S L56 AND E34-E39
L58 18 S L55,L57 AND L15-L19,L24-L57
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 15:04:31 ON 09 OCT 2002

L59 14 S E40-E53
L60 8 S L59 AND L7,L11
L61 6 S L59 AND L20,L23 NOT L60

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:06:09 ON 09 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 OCT 2002 HIGHEST RN 459783-15-4

DICTIONARY FILE UPDATES: 7 OCT 2002 HIGHEST RN 459783-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> d ide can tot 160

L60 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 443128-12-9 REGISTRY
 CN .beta.-Cyclodextrin, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide
 (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C42 H70 O35 . C15 H15 N O2 S
 SR CA
 LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8
 CMF C15 H15 N O2 S




CM 2

CRN 7585-39-9
 CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 443128-11-8 REGISTRY

CN .beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,3A,3B,3C,3D,3E,3F,3G,6A,6B,6C,6D
,6E,6F,6G-heneicosa-O-methyl-, compd. with 2-[(diphenylmethyl)sulfinyl]ace
tamide (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C63 H112 O35 . C15 H15 N O2 S


SR CA

LC STN Files: CA, CAPLUS

CM 1

CRN 68693-11-8

CMF C15 H15 N O2 S




CM 2

CRN 55216-11-0


CMF C63 H112 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN **443128-10-7** REGISTRY
CN .beta.-Cyclodextrin, 2A, 2B, 2C, 2D, 2E, 2F, 2G, 6A, 6B, 6C, 6D, 6E, 6F, 6G-tetradeca-O-methyl-, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide (1:1) (9CI)
(CA INDEX NAME)
MF C56 H98 O35 . C15 H15 N O2 S
SR CA
LC STN Files: CA, CAPLUS


CM 1

CRN 68693-11-8
CMF C15 H15 N O2 S



CM 2

CRN 51166-71-3
CMF C56 H98 O35




1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2002 ACS
 RN **443128-09-4** REGISTRY
 CN .gamma.-Cyclodextrin, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide
 (1:1) (9CI) (CA INDEX NAME)
 MF C48 H80 O40 . C15 H15 N O2 S
 SR CA
 LC STN Files: CA, CAPLUS


CM 1

CRN 68693-11-8
 CMF C15 H15 N O2 S



CM 2

CRN 17465-86-0
 CMF C48 H80 O40




1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2002 ACS
 RN **443128-08-3** REGISTRY
 CN .alpha.-Cyclodextrin, compd. with 2-[(diphenylmethyl)sulfinyl]acetamide
 (1:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C36 H60 O30 . C15 H15 N O2 S
 SR CA
 LC STN Files: CA, CAPLUS

CM 1


CRN 68693-11-8
 CMF C15 H15 N O2 S



CM 2

CRN 10016-20-3
 CMF C36 H60 O30

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:114532

L60 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2002 ACS.

RN 112111-47-4 REGISTRY

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]-, (+)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (+)-Modafinil

CN CRL 40983

FS STEREOSEARCH


MF C15 H15 N O2 S

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:47896

REFERENCE 2: 131:237446

REFERENCE 3: 131:164943

REFERENCE 4: 117:137769

REFERENCE 5: 112:35457

L60 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 112111-43-0 REGISTRY

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]-, (-)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (-)-Modafinil

CN CRL 40982

FS STEREOSEARCH


MF C15 H15 N O2 S

SR CA

LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:47896

REFERENCE 2: 131:237446

REFERENCE 3: 131:164943

REFERENCE 4: 117:137769

REFERENCE 5: 112:35457

L60 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS

RN 68693-11-8 REGISTRY

CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-Modafinil

CN 2-(Benzhydrylsulfinyl)acetamide

CN CEP 1538

CN CRL 40476

CN Modafinil

CN Modiodal

CN Provigil

FS 3D CONCORD

DR 112111-49-6


MF C15 H15 N O2 S

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

140 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 140 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:210420
 REFERENCE 2: 137:179735
 REFERENCE 3: 137:134949
 REFERENCE 4: 137:114532
 REFERENCE 5: 137:109489
 REFERENCE 6: 137:98838
 REFERENCE 7: 137:88283
 REFERENCE 8: 137:57438
 REFERENCE 9: 137:41638
 REFERENCE 10: 137:41220

=> d ide can tot 161

L61 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 55216-11-0 REGISTRY

CN .beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,3A,3B,3C,3D,3E,3F,3G,6A,6B,
 6C,6D,6E,6F,6G-heneicosa-O-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4,7,9,12,14,17,19,22,24,27,29,32,34-Tetradecaaxaocyclo[31.2.2.23
 ,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane, .beta.-cyclodextrin
 deriv.


OTHER NAMES:

CN .beta.-Cyclodextrin permethyl ether
 CN 2,3,6-Tri-O-methyl-.beta.-cyclodextrin
 CN 2,3,6-Trimethyl-.beta.-cyclodextrin
 CN Cydex-.beta.
 CN Heptakis(2,3,6-tri-O-methyl)-.beta.-cyclodextrin
 CN Heptakis(2,3,6-trimethyl)-.beta.-cyclodextrin
 CN Hydrodex .beta.-PM
 CN Permethyl-.beta.-cyclodextrin
 CN Permethylated .beta.-cyclodextrin
 CN Tri-O-methyl-.beta.-cyclodextrin
 CN TRIMEB
 CN Trimethyl-.beta.-cyclodextrin
 FS STEREOSEARCH
 DR 74948-17-7
 MF C63 H112 O35
 CI COM


LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS,
CASREACT, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, PIRA,
TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

550 REFERENCES IN FILE CA (1962 TO DATE)
27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
551 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:185208
REFERENCE 2: 137:184497
REFERENCE 3: 137:179088
REFERENCE 4: 137:114532
REFERENCE 5: 137:83754
REFERENCE 6: 137:83751

REFERENCE 7: 137:68183

REFERENCE 8: 137:68177

REFERENCE 9: 137:37662

REFERENCE 10: 137:33465

L61 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 51166-71-3 REGISTRY

CN .beta.-Cyclodextrin, 2A,2B,2C,2D,2E,2F,2G,6A,6B,6C,6D,6E,6F,6G-tetradeca-O-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4,7,9,12,14,17,19,22,24,27,29,32,34-Tetradeca-oxa-octacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane, .beta.-cyclodextrin deriv.

OTHER NAMES:

CN 2,6-Di-O-methyl-.beta.-cyclodextrin

CN 2,6-Dimethyl-.beta.-cyclodextrin

CN 2A,6A-Di-O-methyl-.beta.-cyclodextrin

CN Beta W7 M 1.8

CN Di-O-methyl-.beta.-cyclodextrin

CN Dimeb

CN Dimethyl-.beta.-cyclodextrin

CN Heptakis(2,6-di-O-methyl)-.beta.-cyclodextrin

CN Heptakis(2,6-di-O-methyl)-.beta.-cyclodextrin

CN Tetradeca-O-methyl-.beta.-cyclodextrin

CN Tetradecakis-2,6-O-methylcycloheptaamylose


DR 120837-54-9, 97568-70-2, 99237-56-6, 95176-10-6, 103346-40-3, 106236-73-1, 84346-59-8, 107031-56-1

MF C56 H98 O35

CI COM

LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CSCHEM, DETHERM*, EMBASE, GMELIN*, IPA, MEDLINE, MSDS-OHS, PHAR, PROMT, RTECS*, TOXCENTER, USPAT2, USPATFULL

(*File contains numerically searchable property data)



1016 REFERENCES IN FILE CA (1962 TO DATE)
 65 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1016 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:185208
 REFERENCE 2: 137:184497
 REFERENCE 3: 137:174673
 REFERENCE 4: 137:129668
 REFERENCE 5: 137:114532
 REFERENCE 6: 137:109576
 REFERENCE 7: 137:90458
 REFERENCE 8: 137:83644
 REFERENCE 9: 137:68183
 REFERENCE 10: 137:68177

L61 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 17465-86-0 REGISTRY

CN .gamma.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-Hexadecaioxanonacyclo[36.2.2.23
 ,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontane,
 .gamma.-cyclodextrin deriv.

OTHER NAMES:

CN .gamma.-Dextrin

CN Cyclomaltooctaose

CN Cyclooctaamylose

CN Dexy Pearl .gamma.-100

CN Ringdex C


CN Stereoisomer of 5,10,15,20,25,30,35,40-octakis(hydroxymethyl)-
 2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-hexadecaaxanonacyclo[36.2.2.23
 ,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontane-
 41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56-hexadecol

DR 216309-81-8, 217487-02-0

MF C48 H80 O40

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES,
 DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS,
 PHAR, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2945 REFERENCES IN FILE CA (1962 TO DATE)
 657 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2956 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:223998

REFERENCE 2: 137:222192

REFERENCE 3: 137:222086

REFERENCE 4: 137:222063

REFERENCE 5: 137:222056

REFERENCE 6: 137:218653

REFERENCE 7: 137:218647

REFERENCE 8: 137:211064

REFERENCE 9: 137:210090

REFERENCE 10: 137:195237

L61 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 12619-70-4 REGISTRY

CN Cyclodextrin (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Celdex

CN Celdex CH 20

CN Celdex CH 30

CN Celdex SH 20

CN Celdex SH 40

CN Celdex TB 50

CN Cycloamylose

CN Cyclodextrins

CN Rhodocap L 20

CN Ringdex P

DR 100091-36-9

MF Unspecified

CI COM, MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
CA, CAPLUS, CASREACT, CBNB, CEN, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, NAPRALERT, PIRA, PROMT,
TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

3462 REFERENCES IN FILE CA (1962 TO DATE)

1076 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3469 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:222054

REFERENCE 2: 137:216133

REFERENCE 3: 137:212301

REFERENCE 4: 137:212297

REFERENCE 5: 137:210054

REFERENCE 6: 137:206536

REFERENCE 7: 137:200358

REFERENCE 8: 137:194679

REFERENCE 9: 137:190770

REFERENCE 10: 137:184455

L61 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 10016-20-3 REGISTRY

CN .alpha.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4,7,9,12,14,17,19,22,24,27,29-Dodecaoxaheptacyclo[26.2.2.2.23,6.28,11.213,
16.218,21.223,26]dotetracontane, .alpha.-cyclodextrin deriv.


CN Cyclohexaamylose (6CI)

OTHER NAMES:

CN .alpha.-Cycloamylose

CN .alpha.-Dextrin
 CN .alpha.-Schardinger dextrin
 CN Alfadex
 CN Celdex A 100
 CN Cyclohexadextrin
 CN Cyclomaltohexaose
 CN Cyclomaltohexose
 CN Dextrin, .alpha.-cyclo
 CN Dexy Pearl .alpha.-100
 CN Ringdex A
 CN Stereoisomer of 5,10,15,20,25,30-hexakis(hydroxymethyl)-
 2,4,7,9,12,14,17,19,22,24,27,29-dodecaoxaheptacyclo[26.2.2.23,6.28,11.213,
 16.218,21.223,26]dotetracontane-31,32,33,34,35,36,37,38,39,40,41,42-
 dodecol
 FS STEREOSEARCH
 DR 23513-50-0, 41871-62-9, 47910-04-3
 MF C36 H60 O30
 CI COM
 LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE,
 GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT,
 NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2,
 USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3820 REFERENCES IN FILE CA (1962 TO DATE)
 762 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3835 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:223998

REFERENCE 2: 137:222192
REFERENCE 3: 137:222063
REFERENCE 4: 137:222056
REFERENCE 5: 137:218653
REFERENCE 6: 137:217146
REFERENCE 7: 137:211064
REFERENCE 8: 137:210090
REFERENCE 9: 137:201551
REFERENCE 10: 137:197713

L61 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2002 ACS

RN 7585-39-9 REGISTRY

CN .beta.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4,7,9,12,14,17,19,22,24,27,29,32,34-Tetradecaaxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane, .beta.-cyclodextrin deriv.

CN Cycloheptaamylose (7CI)

OTHER NAMES:

CN .beta.-Cycloamylose

CN .beta.-Cycloheptaamylose

CN .beta.-Dextrin

CN Betadex

CN Cavamax W 7

CN Celdex B 100

CN Celdex N

CN Cycloheptaglucan

CN Cycloheptaglucosan

CN Cyclomaltoheptaose

CN Dextrin, .beta.-cyclo

CN Kleptose

CN Kleptose B

CN NSC 314334

CN Rhodocap N

CN Ringdex B

CN Ringdex BL

CN Schardinger .beta.-dextrin

CN Stereoisomer of 5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaaxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol

FS STEREOSEARCH

DR 449728-55-6, 37331-89-8, 47918-72-9

MF C42 H70 O35

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU, VTB


(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9909 REFERENCES IN FILE CA (1962 TO DATE)
 3657 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 10004 REFERENCES IN FILE CAPLUS (1962 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 137:225951
 REFERENCE 2: 137:223998
 REFERENCE 3: 137:223323
 REFERENCE 4: 137:222192
 REFERENCE 5: 137:222187
 REFERENCE 6: 137:222185
 REFERENCE 7: 137:222063
 REFERENCE 8: 137:222056
 REFERENCE 9: 137:221916